Predictive Role of IGFBP-7 and Activin A in Newly Diagnosis of Multiple Myeloma
Keywords:
Plasma Cell Tumor, MM, Newly diagnosis, Predictive Biomarkers, IGFBP7, Activin AAbstract
Plasma cells tumor or multiple myeloma (MM) is a hematological malignancy and determined the second most common cancer characterized by extensive renal deficiency, lytic lesions of bone, anemia, hypercalcemia and recurrent infections; despite emerging novel approaches and agents, it still incurable. IGFBP-7 is high expressed in liver, kidney, bone and muscle, and the expression level is higher in renal tubules. Activin A is a dimeric glycoprotein, it controls the transcription of downstream target genes; and noncanonical signaling pathways, including as mitogen-activated protein kinase signaling. Aim of the study: Is found the correlation between predictive biomarkers IGFBP-7 and Activin A in newly diagnosed plasma cells tumor. Materials and methods: Cross-sectional study of patients Hospital-Based was conducted from the period extended from May 2020 until August 2021. A total of 58 newly diagnosis MM patients were involved in this study who were subjected to physical examination, standard clinical, radiological, and laboratory investigations and diagnosed by hematologists with MM from both genders. Urine samples were collected to measure the concentrations of IGFBP7 Activin A By ELISA analysis. Results: The mean age of newly diagnosis of patients was (61.69 ± 11.12) years. 80.0 years was the older age and the youngest patient was (34.0) years. Half of them and more were male with (53.4%). According to staging distribution of disease (Stage I, Stage II and Stage III). Stage I represent (37.9%), Stage II represent (27.6%) of patients) and Stage III represent (34.5%) of patients. The mean differences of IGFBP7 (pg/ml) according to stages of MM. There were significant differences between means of IGFBP7 (pg/ml) according to stages of the disease. While, the mean differences of Activin A (ng/ml) according to staging of the disease, there were significant differences between means of Activin A (ng/ml) according to stages of multiple myeloma.
Downloads
References
Sandecká, V.; Pour, L.; Špička, I.; Minařík,
J.; Radocha, J.; Jelínek, T.; Heindorfer,
A.; Pavlíček, P.; l Sýkora, M.; Jungová,
A. et al., (2021). Bortezomib-based
therapy for newly diagnosed multiple
myeloma patients ineligible for autologous
stem cell transplantation: Czech Registry
Data. Eur J Haematol. ;107(4):466-474.
Moritz, D. Y. (2019). Multiple myeloma and
other plasma cell diseases (Doctoral
dissertation, University of Zagreb. School of
Medicine. Department of Internal Medicine.
Salman, A. S.; Saleh, E. S. and Abass, M. S.
(2020). Estimation of Beta Two
Microglobulins, Fetuin-A, Resistin Serum
Level in Iraqi Multiple Myeloma Patients
Iraqi J Pharm Sci, 29(2).
Soh, K. T. and Wallace, P. K. (2021). Evaluation
of measurable residual disease in multiple
myeloma by multiparametric flow cytometry:
Current paradigm, guidelines, and future
applications. International Journal of
Laboratory Hematology, 43: 43-53.
Hemminki, K.; Försti, A. and Hansson, M.
(2021). Incidence, mortality and survival
in multiple myeloma compared to other
hematopoietic neoplasms in Sweden up to
year 2016. Scientific reports, 11(1): 1-10.
Rajaram, S.; Baylink, D. J. and Mohan, S.
(1997). Insulin-like growth factor-binding
proteins in serum and other biological
fluids: regulation and functions. Endocrine
reviews, 18(6): 801-831.
Hamid, G. S.; Allawi, A. A. and Ghudhaib,
K. K. (2021). Correlation of Pentosidine
with Kidney Diseases in Iraqi Patients with
Diabetic Nephropathy. Iraqi Journal of
Science, 62(10): 3436-3442
Sato, Y.; Chen, Z.; Miyazaki, K. (2007) Strong
suppression of tumor growth by insulin-like
growth factor-binding protein-related protein
/tumor-derived cell adhesion factor/mac25.
Cancer Sci, 98: 1055-1063.
Farmer, S. M. and Andl, C. D. (2021).
Computational modeling of transforming
growth factor β and activin a receptor complex
formation in the context of promiscuous
signaling regulation. Journal of Biomolecular
Structure and Dynamics, 39(14): 5166-5181.
Bloise, E.; Ciarmela, P.; Dela Cruz, C.; Luisi,
S.; Petraglia, F. and Reis, F. M. (2019).
Activin A in mammalian physiology.
Physiological reviews, 99(1):739-780.
Kyle, R.A.; Gertz, M.A.; Witzig, T.E.; Lust, J.A.;
Lacy, M.Q.; Dispenzieri, A.; Fonseca, R.;
Rajkumar, S.V.; Offord, J. R.; Larson, D. R.;
Plevak, M.E.; Therneau, T.M. and Greipp,
P.R. (2003) Review of 1,027 patients withnewly diagnosed multiple myeloma. Mayo
Clinic Proc; 78: 21-33.
Lin, J.; Markowitz, G. S.; Valeri, A. M.;
Kambham, N.; Sherman, W. H.; Appel,
G. B. and D'AGATI, V. D. (2001). Renal
monoclonal immunoglobulin deposition
disease: the disease spectrum. Journal of
the American Society of Nephrology,
(7): 1482-1492.
Dimopoulos, M. A.; Kastritis, E.; Rosinol, L.;
Bladé, J. and Ludwig, H. (2008).
Pathogenesis and treatment of renal failure
in multiple myeloma. Leukemia, 22(8):
-1493.
Mohsin, A. J.; Hussein, T. A.; Mohammed,
S. N. and Mohammed A. Essa, M. A.
(2014). The role of TNF-α in the
pathogenesis of multiple myeloma “a study
in Iraqi patients”. Baghdad Science
Journal ,11(2).
Jumaah, H. M.; Yenzeel, J H.; and Mehdi, M.
G. (2021). Evaluation of Some Biochemical
Parameters and Hormones in Patients with
Acute Myeloid Leukemia in Iraq. Iraqi
Journal of Science, 62(5): 1460-1466.
Ou, Z.; Gao, Y.; Yu, D.; Jiang, D.; Cui, J.;
Zhang, Y.; Tang, S.; Duan, D. and Wang,
Z. (2022). The burden and trends of
multiple myeloma worldwide from 1990 to
https://assets.researchsquare.com/files/rs-
/v2/802af9f2-5b7a-4b7e-b353-
b6592d7c12c.pdf?c=1663784564
Cook, M. B.; McGlynn, K. A.; Devesa, S. S.;
Freedman, N. D. and Anderson, W.F.
(2011). Sex disparities in cancer mortality
and survival. Cancer Epidemiol Prev
Biomark.;20:1629-37.
Derman, B. A.; Langerman, S. S.; Maric, M.;
Jakubowiak, A.; Zhang, W. and Chiu,
B.C. (2021). Sex differences in outcomes
in multiple myeloma. British Journal of
Haematology; 192, 66-69.
Mihou, D.; Katodritou, E. and Zervas, K.
(2007). Multiple myeloma staging based
on the combination of beta-2-
microglobulin and albumin: The role of
albumin in the model. Hematology; 12(6):
-531.
Shaikh, S. P.; Irfan, S. M. and Sheikh, S. S.
(2019). Disease staging according to
international scoring system in newly
diagnosed patients with multiple myeloma.
Pak J Med Sci.; 35(1): 90-94.
Posch, D.; Rabitsch, W.; Wohlfarth, P.; Leiner, M.;
Porpaczy, E.; Drach, J.; Raderer ,M. and
Lamm, W. (2017). Gender-Specific Aspects in
Patients with Multiple Myeloma Undergoing
Autologous Stem Cell Transplantation: A SingleCenter Experience. Oncology; 93:295-301.
Mohammed, N.; Baba, K.S.; Yadagiri, B.,
Gundeti, S. and Raju, S. B. (2019).
Biochemical Characterization of Multiple
Myeloma Patients across ISS Stages – A Data
Base Workup from a Tertiary Care Hospital in
India. Asian Pac J Cancer Care; 4(3) :77-82.
Woziwodzka, K.; Malyszko, J.; Koc-Żórawska, E;
Żórawski, M; Dumnicka, P; Jurczyszyn, A;
Batko, K. et al., (2021). Renal Impairment
Detectors: IGFBP-7 and NGAL as Tubular
Injury Markers in Multiple Myeloma Patients.
Medicina (Kaunas); 57(12): 1348.
Woziwodzka, K.; Malyszko, J.; Koc-
Żórawska, E.; Żórawski, M.; Dumnicka, P.;
Jurczyszyn, A.; Batko, K.; Mazur, P. et
al., (2022). Title Transgelin-2 in Multiple
Myeloma: A New Marker of Renal
Impairment?. Molecules, 27:79.
Dimopoulos, M.; Delimpasi, S.; Katodritou, E.;
Vassou, A.; Kyrtsonis, M.C.; Repousis, P.;
Kartasis, Z.; Parcharidou, A.; Michael, M.;
Michalis, E.; et al. (2014). Significant
improvement in the survival of patients with
multiple myeloma presenting with severe
renal impairment after the introduction of
novel agents. Ann. Oncol., 25:195-200.
Huang, X.; Hong, C.; Peng, Y.; Yang, S.;
Huang, L.; Liu, C.; Chen, L.; Chu, L.;
Xu, L. and Xu, Y. (2019). The Diagnostic
Value of Serum IGFBP7 in Patients with
Esophageal Squamous Cell Carcinoma
,10(12): 2687-2693.
Iriuchishima, H.; Maeshima, A.; Takahashi, S.;
Ishizaki, T.; Yokohama, A.; Tsukamoto, N.;
Saitoh, T.; Murakami, H. and Handa, H.
(2019). Bioscience Reports, 39.
Terpos, E.; Kastritis, E.; Christoulas, D.;
Gkotzamanidou, M.; Eleutherakis-Papaiakovou,
E.; Kanellias, N.; Papatheodorou, A. and
Dimopoulos, M. A. (2012). Circulating
activin-A is elevated in patients with advanced
multiple myeloma and correlates with extensive
bone involvement and inferior survival; no
alterations post-lenalidomide anddexamethasone therapy. Annals of Oncology,
: 2681-2686.
Hvidberg, V; Jacobsen, C.; Strong, R.K.;
Cowland, J.B.; Moestrup, S.K. and
Borregaard, N. (2005). The endocytic
receptor megalin binds the iron
transporting neutrophil-gelatinaseassociated lipocalin with high affinity and
mediates its cellular uptake. FEBS Lett.
, 773-777.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
